The disassembly of these nanoparticles upon FAP-α cleavage led to the efficient release of the encapsulated drugs at tumour sites, and superior therapeutic efficacy for a variety of solid experimental tumours including xenograft MCF-7 breast tumour models [162]. The gene discussed is FAP; the disease is neoplasm.